Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

March 29-30, 2019

New York, New York

Continuing Medical Education

ACCME

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

Imedex, LLC designates this live educational activity for a maximum of 13.0 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.



Maintenance of Certification (MOC)
Successful completion of this CME activity enables a participant to earn up to 13.0 MOC points towards the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points.

ABIM Diplomates will have 60 days from the conclusion of the conference (deadline is 5/25/2018) to claim MOC points and must be able to provide to Imedex the correct ID number, DOB (MM/DD) and name as registered at ABIM.

Nursing
This activity has been planned and implemented in accordance with the Essential Areas and policies of the American Nurses Credentialing Center (ANCC) through the joint providership of North American Center for Continuing Medical Education, LLC (NACCME), and Imedex.  The North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

This continuing nursing education activity awards 13.0 contact hours

Provider approved by the California Board of Registered Nursing, Provider #13255 for 13.0 contact hours.

Pharmacy
Imedex, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge activity (0408-0000-18-002-L01-P) has been approved for a maximum of 13.0 contact hours (1.3 CEUs). To receive credit, participants must complete an activity evaluation survey. In order to claim credit in a timely matter, you must submit your evaluation and credit request within 60 days (deadline is 5/25/2018).

Pharmacists must be able to provide their correct NABP number and DOB (MM/DD). Imedex is responsible for submitting data through CPE Monitor.


Who Should Attend
This educational activity is specifically designed to meet the educational needs of community oncologists and other healthcare professionals (physicians-in-training, oncology nurses, pharmacists, physician assistants, etc.) involved in the therapeutic management of patients with GI cancers.


Objectives
Upon completion of these educational activities, participants should be better able to:

    • Analyze the mechanism of action (MOA) and safety-efficacy profiles of currently approved and emerging oncological agents including immunotherapies for the management of GI malignancies
    • Integrate clinical trial data and evidence-based therapies for improving clinical outcomes in patients with GI malignancies
    • Evaluate the best practices and standards of care based on a multidisciplinary approach for the management of GI cancers
    • Implement the rational use of immunotherapies in patients with GI malignancies on a case-by case basis
    • Define patient populations most suitable for enrolling in GI clinical trials for progressive advanced stage GI malignancies
    • Implement optimal management strategies for both metastatic and non-metastatic GI malignancies based on personalized factors such as comorbidities, cost, disease stage, and prior therapeutic regimens